Institutional members access full text with Ovid®

Share this article on:

Cancer risk among men with, or at risk of, HIV infection in southern Europe

Serraino, Diegoa; Boschini, Antoniob; Carrieri, Patriziac; Pradier, Christiande; Dorrucci, Mariafg; Maso, Luigino Dalh; Ballarini, Paolob; Pezzotti, Patriziofg; Smacchia, Camillob; Pesce, Alainde; Ippolito, Giuseppea; Franceschi, Silviah; Rezza, Giovannifg

Epidemiology & Social

Objective: To evaluate the cancer risk in southern European men with, or at risk of, HIV infection.

Design: An analysis of longitudinal data to assess time-dependent rare events.

Methods: Data from a cohort of HIV seroconverters, and from two hospital-based HIV seroprevalent cohorts were combined and analysed. The number of cancer cases observed was compared with the expected number, obtained from cancer incidence rates among men in the general population. Age-standardized incidence ratios (SIR) and their 95% confidence intervals (CI) were computed.

Results: A total of 19 609 person-years of observation were accumulated among HIV-positive men, and 7957 person-years among HIV-negative men. Among HIV-positive men, statistically significant increased SIR were seen for Hodgkin's disease (HD) (SIR = 8.7), liver cancer (SIR = 11.0), and cancer of the salivary glands (SIR = 33.6). An excess of lung cancer was seen among intravenous drug users (IDU), but not among homosexual men. When the risk of all non-AIDS-defining cancers was considered, HIV-positive men had a nearly twofold excess (95% CI: 1.2–2.8). A risk of similar magnitude emerged among HIV-negative IDU (95% CI: 1.0–4.5), largely attributable to lung cancer and HD.

Conclusion: These findings confirm that HIV infection increases the risk of HD, whereas they suggest that the risk of hepatocellular carcinoma may also be enhanced by HIV infection. The observation of an elevated risk of lung cancer in both HIV-positive and HIV-negative IDU points to personal behaviours unrelated to HIV infection.

From the aCentro di Riferimento AIDS e Servizio di Epidemiologia delle Malattie Infettive, IRCCS Lazzaro Spallanzani, Rome, Italy; bCentro Medico, Comunità di San Patrignano, Rimini, Italy; cINSERM U 379, Marseille, France; dCISIH-University Hospital, Nice, France; eon behalf of the DMI-2 Study Group (see Appendix); fCentro Operativo AIDS, Istituto Superiore di Sanità, Rome, Italy; gfor the Italian HIV Seroconversion Study Group (see Appendix); and hServizio di Epidemiologia, IRCCS Centro di Riferimento Oncologico, Aviano, Italy.

Sponsorship: Funding for this project was provided by II° Programma Nazionale di Ricerca sull'AIDS, Istituto Superiore di Sanità, Italy, and by Ricerca Corrente IRCCS Lazzaro Spallanzani, Italian Ministry of Health.

Requests for reprints to: Diego Serraino, Centro di Riferimento AIDS e Servizio di Epidemiologia delle Malattie Infettive, IRCCS Lazzaro Spallanzani, via Portuense 292, 00149 Rome, Italy.

Received: 10 December 1999; accepted: 22 December 1999.

© 2000 Lippincott Williams & Wilkins, Inc.